Ceregene, Inc.

27 articles about Ceregene, Inc.

• 

  BioSpace Movers and Shakers - Oct. 22

  10/22/2018

  Execs at Novo Nordisk, AbbVie, and more made moves this week. Here's a roundup of those changes.

• Sangamo BioSciences, Inc. to Acquire Ceregene, Inc.

  8/27/2013

• Ceregene, Inc. Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study

  5/21/2013

• Ceregene, Inc. Reports Data From Parkinson's Disease Phase 2b Study

  4/22/2013

• Ceregene, Inc. and Alzheimer's Disease Cooperative Study Group Complete Enrollment of CERE-110 Phase 2 Trial

  3/13/2013

• Ceregene, Inc. Parkinson's Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin)

  5/17/2012

• Ceregene, Inc. Completes Enrollment of Second Phase 2 Study of CERE-120 for the Treatment of Parkinson's Disease

  12/1/2011

• Ceregene, Inc. Reports New Findings Regarding How Parkinson's Brains Respond to Neurotrophic Factors

  2/15/2011

• Ceregene, Inc. Advances Phase 2b CERE-120 (AAV2-neurturin) Trial in Parkinson's Disease

  2/3/2011

• Ceregene, Inc. Raises $11.5 Million in Series D Financing

  11/11/2010

• Ceregene, Inc. Initiates a New Controlled Phase 2b Trial of CERE-120 for Parkinson's Disease

  10/20/2010

• Ceregene, Inc. Initiates a New Controlled Phase 2b Trial of Cere-120 for Parkinson's Disease

  10/19/2010

• Ceregene, Inc. Has Initiated A New Phase 1/2 Trial Of Cere-120 For Parkinson’s Disease

  4/29/2010

• Ceregene, Inc. Receives Additional Grant From The Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients

  8/5/2009

• Ceregene, Inc. Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinson's Disease

  5/27/2009

• Ceregene, Inc. Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinson's Disease

  11/26/2008

• Ceregene, Inc. Phase 2 Clinical Trial for Alzheimer's Disease to be Funded by $5.4 Million Grant From National Institutes of Health (NIH)

  11/4/2008

• Ceregene, Inc. Announces Two Key Additions to Leadership Team

  4/23/2008

• Ceregene, Inc. Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinson's Disease

  12/12/2007

• Ceregene, Inc. Promotes Dr. Raymond Bartus to Executive Vice President

  12/6/2007